A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study toAssess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies
INVICTUS Study of Drug in Advanced Gastrointestinal Stromal Tumors
Sponsor: Deciphera Pharmaceuticals, LLC
Enrolling: Male and Female Patients
IRB Number: AAAR6045
U.S. Govt. ID: NCT03353753
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: Deciphera Pharmaceuticals, LLC., the Sponsor of this study, is developing a drug called DCC-2618 to treat Gastrointestinal Stromal Tumors (GIST) that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the instructions are no longer correct. DCC-2618 is designed to block signals from genes that cause cancer to grow. The study is being done to learn more about the safety of the study drug and how well it works against cancer in patients who have received prior anticancer treatments. We will also look at how DCC-2618 may affect your body.
This study is closed
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with GIST? Yes No
Have you received prior anticancer treatment? Yes No
Are you willing and able to comply with study procedures and restrictions? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator